表紙
市場調査レポート

世界のアンチセンス・RNAi治療薬市場の将来動向

Global Antisense and RNAi Therapeutics Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 318835
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
世界のアンチセンス・RNAi治療薬市場の将来動向 Global Antisense and RNAi Therapeutics Market 2015-2019
出版日: 2014年11月12日 ページ情報: 英文 70 Pages
概要

アンチセンスおよびRNAi治療は、重篤な慢性疾患および希少疾患の治療法で使用される、新しい画期的な治療選択肢です。RNAiとは、RNA分子が明確なmRNA分子を滅却することによって遺伝子発現を阻害する、というRNAベースの遺伝子発現抑制プロセスです。アンチセンス技術には、mRNAやmRNA前駆体のスプライシング部位と結合して、その活動を効果的に不活性化させるような、拡散鎖の合成が含まれています。RNAiおよびアンチセンスは、研究、診断および治療といった様々な用途のために、製薬企業や研究機関およびその他によって使用される主要技術です。RNAi治療薬には、がんや神経変性障害のような多様な疾患の治療に適用できます。RNAi技術で使用されるRNA分子には、miRNAおよびsiRNAの2種類があります。世界のアンチセンス・RNAi治療薬市場の2013〜2018年の年平均成長率(CAGR)は10.86%に達する、と予測されています。

当レポートでは、全世界のアンチセンスおよびRNAi(RNA干渉)の治療薬市場について分析し、市場の概要や構造、市場規模の動向(今後5年間の予測値)、技術別・治療分野別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 技術別の市場区分

第8章 治療分野による市場区分

第9章 地理区分

  • 南北アメリカのアンチセンス・RNAi治療薬市場
  • 欧州・中東・アフリカ(EMEA)地域のアンチセンス・RNAi治療薬市場
  • アジア太平洋地域のアンチセンス・RNAi治療薬市場

第10章 購入基準

第11章 パイプライン製品の現状

第12章 市場成長因子

第13章 成長因子とその影響

第14章 市場の課題

第15章 成長因子と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • 企業合併・買収(M&A)および共同開発
  • ベンダー分析
  • その他の有力ベンダー

第19章 主要ベンダーの分析

  • Alnylam Pharmaceuticals
    • 主要データ
    • 事業概要
    • 財務実績
    • 最近の発展動向
    • SWOT分析
  • Isis Pharmaceuticals
  • Sanofi SA
  • Tekmira Pharmaceuticals

第20章 関連レポート

図表一覧

目次
Product Code: IRTNTR4600

About Antisense and RNAi Therapeutics

Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site on pre-mRNA and inactivates it effectively. RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA.

TechNavio's analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Antisense and RNAi Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of antisense and RNAi therapeutics used for the treatment of various serious chronic diseases including:

  • Infectious diseases
  • Cardiovascular diseases
  • Kidney diseases
  • Cancer
  • Metabolic disorders
  • Others

The report also covers the two main technologies, i.e., Antisense and RNAi technology, which are used by vendors to develop antisense and RNAi therapeutics.

TechNavio's report, the Global Antisense and RNAi Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Antisense and RNAi Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Alnylam Pharmaceuticals
  • Isis Pharmaceuticals
  • Sanofi
  • Tekmira Pharmaceuticals

Other Prominent Vendors

  • Acuitas Therapeutics
  • Allergan
  • Antisense Therapeutics
  • Ascletis
  • AstraZeneca
  • Atlantic Pharmaceuticals
  • Benitec Biopharma
  • Biogen Idec
  • Bristol-Myers Squibb
  • Dainippon Sumitomo Pharma
  • Dicerna Pharmaceuticals
  • Enzon Pharmaceuticals
  • F. Hoffmann-La Roche
  • Glaxosmithkline
  • Gradalis
  • iCo Therapeutics
  • Kyowa Hakko Kirin
  • Marina Biotech
  • Novartis
  • OncoGenex Pharmaceuticals
  • OPKO Health
  • Pfizer
  • Quark Pharmaceuticals
  • Regulus Therapeutics
  • Silence Therapeutics
  • Spectrum Pharmaceuticals
  • Sylentis
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • The Medicines Company
  • TransDerm

Market Driver

  • Advances in Technology
  • For a full, detailed list, view our report

Market Challenge

  • Toxicity of Antisense and RNAi Molecules-based Drugs
  • For a full, detailed list, view our report

Market Trend

  • Increased Strategic Collaborations and Licensing Activities
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Technology

08. Market Segmentation by Therapeutics Area

09. Geographical Segmentation

  • 09.1. Antisense and RNAi Therapeutics Market in Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. Antisense and RNAi Therapeutics Market in EMEA Region
    • 09.2.1. Market Size and Forecast
  • 09.3. Antisense and RNAi Therapeutics Market in APAC Region
    • 09.3.1. Market Size and Forecast

10. Buying Criteria

11. Pipeline Snapshot

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions and Collaborations
  • 18.2. Vendor Analysis 2014
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Alnylam Pharmaceuticals
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Financial Performance
    • 19.1.4. Recent Developments
    • 19.1.5. SWOT Analysis
  • 19.2. Isis Pharmaceuticals
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Revenue Comparison 2011 and 2013
    • 19.2.4. Recent Developments
    • 19.2.5. SWOT Analysis
  • 19.3. Sanofi SA
    • 19.3.1. Key Facts
    • 19.3.2. Business Description
    • 19.3.3. Business Segmentation
    • 19.3.4. Revenue by Business Segmentation
    • 19.3.5. Revenue Comparison 2012 and 2013
    • 19.3.6. Sales by Geography
    • 19.3.7. Business Strategy
    • 19.3.8. Key Developments
    • 19.3.9. SWOT Analysis
  • 19.4. Tekmira Pharmaceuticals
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Financial Performance
    • 19.4.4. Key Developments
    • 19.4.5. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Antisense and RNAi Therapeutics Market 2014-2019 (US$ million)
  • Exhibit 3: Global Antisense and RNAi Therapeutics Market Segmentation by Technology
  • Exhibit 4: Global Antisense and RNAi Therapeutics Market Segmentation by Technology 2014
  • Exhibit 5: Global Antisense and RNAi Therapeutics Market by Therapeutics Area
  • Exhibit 6: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014
  • Exhibit 7: Antisense and RNAi Therapeutics Market in Americas 2014-2019 (US$ million)
  • Exhibit 8: Antisense and RNAi Therapeutics Market in EMEA Region 2014-2019 (US$ million)
  • Exhibit 9: Antisense and RNAi Therapeutics Market in APAC Region 2014-2019 (US$ million)
  • Exhibit 10: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014-2019 (US$ million)
  • Exhibit 11: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014-2019
  • Exhibit 12: Alnylam Pharmaceuticals: Financial Performance 2013-2012 (in million)
  • Exhibit 13: Isis Pharmaceuticals: Revenue Comparison 2011 and 2013(US$ million)
  • Exhibit 14: Sanofi SA: Business Segmentation
  • Exhibit 15: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 16: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 17: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 18: Tekmira Pharmaceuticals: Financial Performance 2012-2013
Back to Top